Clinical Trials Browser

Phase 2 × INDUSTRY × Ototoxicity × Clear all

NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Phase 2 Withdrawn

Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

NCT03480971 2024-11-20

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Phase 2 Recruiting

Ototoxicity, Mucositis